BIO and other proponents of the biotech industry are continuing efforts to encourage Congress and the Trump administration to produce policies that are favorable to the industry and address vital issues such as capping the prices of renewable identification numbers. BIO's Erick Lutt, director of industrial and environmental policy, said the industry needs stable policies to "help continue to drive investment and advance in cellulosic biofuel technologies."
An exclusive distribution agreement was reached by Valeritas and Med Trust for the commercialization of Valeritas' V-Go insulin delivery device in Germany and Austria. Under the deal, sales, marketing and distribution activities for the product will be handled by Med Trust, while product development, quality management, regulatory approval and manufacturing will be managed by Valeritas.
Ankit Shah was tapped to serve as senior director of commercialization and marketing at SetPoint Medical. Shah most recently was senior director of marketing and business at Intersect ENT.
Isabelle Raymond, former director of scientific and professional affairs at Exeltis, was named vice president of clinical development at Sensus Healthcare. Raymond previously served as director of medical affairs at EternoGen and senior medical science liaison at Valeant Pharmaceuticals.
Motus GI secured a patent from the Chinese Patent Office for its Pure-Vu System, which is designed for cleansing the colon to improve visualization in colonoscopy. The system is used with standard colonoscopes to allow for cleaning during colonoscopies while standard procedural workflow and techniques are preserved.
The second Connected Health Innovation Award was launched by Zimmer Biomet in the Europe, Middle East and Africa region to discover digital technologies for improving musculoskeletal and orthopedic treatment outcomes and benefiting health care providers with cost efficiencies. The competition is open to applicants with a market-ready, approved-for-commercialization product that has at least two or three first users and will award the winner about $29,400 in cash, plus support for piloting and promoting the product.
The FDA gave Xtant Medical clearance to market its InTice-C Porous Titanium Cervical Interbody System, which is intended for optimizing vascularization to the fusion site. The system offers a number of height, footprint and endplate options and provides migration resistance using machined endplate structures in combination with porous titanium.
AstraZeneca's new ad within an ad for its asthma treatment Fasenra shows patients watching a roomful of TV scientists explaining how eosinophils may be a cause of the condition. "We wanted to bring to life the idea that scientists [which are portrayed by actors in the ad] are sharing important information to and for people with severe uncontrolled asthma while showing how those potential patients are reacting to receiving the new insight," said AstraZeneca's Mina Makar.